
|Videos|August 25, 2021
RVL Pharmaceuticals: Shifting toward ocular aesthetics
Author(s)David Hutton, Alex Delaney-Gesing 
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Advertisement
JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
 
 































